Register Login
Register to leave comments
  • News bot July 31, 2026, 11:52 a.m.

    📋 ABBVIE INC. (ABBV) - Financial Results

    Filing Date: 2026-07-31

    Accepted: 2026-07-31 07:51:32

    Event Type: Financial Results

    Event Details:

    ABBVIE INC. (ABBV) Reports the reporting period Financial Results ABBVIE INC. (ABBV) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 16990
    • Net Income: 3613
    • EPS: 3.65
    • Cash and equivalents: $12,861
      • targeting IL-13 for atopic dermatitis (AD), as well as APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP) in asthma. The acquisition holds potential for substantial shareholder value creation, with mega-blockbuster peak sales potential across Apogee's pipeline of assets, and is expected to close in the third quarter of 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    In Millions Except Per Share Data Selling General Administrative 3.25K 7.21K $-3.96K -54.88%
    In Millions Except Per Share Data Total Operating Expenses 10.53K 21.57K $-11.04K -51.19%
    Interest Expense 678.00 1.32K $-646.00 -48.79%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ABBVIE INC.
    • Ticker Symbol: ABBV

Search

News categories